Diabetes drug combo shows Long-Term safety in new study

NCT ID NCT02622113

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at the long-term safety and effectiveness of adding canagliflozin to insulin therapy in adults with type 2 diabetes. A total of 139 people who had completed a previous 16-week study took part. Researchers tracked side effects, blood sugar control, and weight changes over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

139 people

The number who actually took part.

Start date

Dec 2014

Finished

Apr 2016

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients should complete the week 16 assessments in the double-blind study (TA-7284-11) Exclusion Criteria: * Patients with hereditary glucose-galactose malabsorption or primary renal glucosuria * Patients with severe diabetic complications (proliferative diabetic retinopathy, stage 4 nephropathy, or serious diabetic neuropathy) * Patients with serious renal or hepatic disease * Patients who are the excessive alcohol addicts * Patients who are pregnant, lactating and probably pregnant patients and patients who can not agree to contraception

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes mellitus are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Insulin Resistance type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Reserch site

    Chugoku, Japan

  • Reserch site

    Chūbu, Japan

  • Reserch site

    Hokkaido, Japan

  • Reserch site

    Kanto, Japan

  • Reserch site

    Kinki, Japan

  • Reserch site

    Kyushu, Japan

  • Reserch site

    Tōhoku, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.